NCT07405723 Arm Position and Blood Pressure Measurement Accuracy During Pregnancy
| NCT ID | NCT07405723 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sheba Medical Center |
| Condition | Pregnancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-04-12 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2026-04-12 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Accurate blood pressure measurement is essential during pregnancy, as blood pressure readings guide clinical decisions related to the diagnosis and management of hypertensive disorders of pregnancy. Clinical guidelines recommend measuring blood pressure with the arm supported at heart level; however, in routine practice, blood pressure is often measured with the arm in non-standard positions. This study aims to evaluate how different arm positions affect blood pressure measurements in pregnant women. Pregnant women attending a high-risk pregnancy clinic will undergo blood pressure measurements with the arm placed in several commonly used positions, including supported at heart level, supported on the lap, and unsupported at the side. Each participant will have multiple measurements taken during a single clinic visit. The study is designed as a randomized crossover trial with stratification by trimester and chronic hypertension status, allowing each participant to serve as her own control. Participants will be enrolled across all three trimesters of pregnancy, and results will be analyzed separately for each trimester. The primary outcome is the difference in systolic and diastolic blood pressure measurements between arm positions. The findings of this study may help improve the accuracy of blood pressure measurement during pregnancy and inform clinical practice regarding optimal measurement techniques.
Eligibility Criteria
Inclusion Criteria: * Pregnant women aged 18 to 55 years * Singleton or multiple viable intrauterine pregnancy * Gestational age corresponding to first, second, or third trimester at the time of enrollment * Ability to sit upright comfortably for the duration of blood pressure measurements * Ability to understand the study procedures and provide written informed consent Exclusion Criteria: * Preexisting significant cardiac disease (e.g., arrhythmias, congenital heart disease, severe valvular disease) * Chronic kidney disease defined as serum creatinine ≥1.5 mg/dL at enrollment * Significant upper limb or shoulder conditions that may affect arm positioning or blood pressure measurement (e.g., lymphedema, fractures, prior surgery, arteriovenous fistula) * Neurological or musculoskeletal conditions preventing proper positioning * Severe preeclampsia, eclampsia, or other acute medical conditions requiring immediate intervention * Major fetal anomaly * Intrauterine fetal demise
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07405723 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 55 Years, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07405723 currently recruiting?
Yes, NCT07405723 is actively recruiting participants. Contact the research team at michalaxelrod2805@gmail.com for enrollment information.
Where is the NCT07405723 trial being conducted?
This trial is being conducted at Ramat Gan, Israel.
Who is sponsoring the NCT07405723 clinical trial?
NCT07405723 is sponsored by Sheba Medical Center. The trial plans to enroll 300 participants.